Samuraciclib
- Generic Name
- Samuraciclib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C22H30N6O
- CAS Number
- 1805833-75-3
- Unique Ingredient Identifier
- 46D4HS9ODA
- Background
Samuraciclib is under investigation in clinical trial NCT03363893 (Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies).
- Associated Conditions
- -
- Associated Therapies
- -
Breast Cancer Clinical Trial Pipeline Appears Robust With
DelveInsight's 'Breast Cancer Pipeline Insight 2024' highlights a robust pipeline with 100+ companies developing 120+ drugs, driven by rising incidence, tech advancements, and increased awareness. Key companies and drugs include Ambrx, CSPC ZhongQi, Merus, and ARX788, DP303c, SHR-A1811, among others. FDA fast-track designations and breakthrough therapy designations for drugs like 9MW2821 and inavolisib underscore significant progress.
Carrick Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT7439
Carrick Therapeutics initiates Phase 1 trial for CT7439, a novel CDK12/13 inhibitor and Cyclin-K glue-degrader, targeting advanced solid tumors. The trial aims to assess safety and pharmacokinetics, with potential for combination therapy in multiple cancer types.
Related Clinical Trials:
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath